Puma Biotech Q1 net loss $4.8M vs prior year net income; NERLYNX revenue down 14%

PUMA BIOTECHNOLOGY, INC.

2024-Q1 EPS reported -$0.10 revenue$43,766,000

Net product revenue $40.3M (Q1 2023: $46.8M); total revenue $43.8M including $3.5M royalties.
GAAP net loss $0.10/shr; non-GAAP adjusted net loss $0.05/shr vs adjusted net income $0.09/shr in Q1 2023.
Cash, cash equivalents and marketable securities $107.2M at March 31, 2024; operating cash flow $11.3M.
Q2 2024 guidance: net product revenue $43-45M, net loss $(6)-(9)M; FY2024: product revenue $183-190M, net income $12-15M.
Initiated alisertib Phase II trial in small cell lung cancer (ALISCA-Lung1); key milestones through Q4 2024.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

PUMA BIOTECHNOLOGY, INC. reported the first quarter ended March 31, 2024 results: revenue $43.8 million, net income net loss of $4.8 million, EPS $0.10 per basic and diluted share.

Period: the first quarter ended March 31, 2024
Revenue: $43.8 million
Net income: net loss of $4.8 million
EPS: $0.10 per basic and diluted share
Result: reported results

Exact text from the filing

sales of NERLYNX, Puma’s first commercial product, license revenue from Puma’s sub-licensees and royalty revenue. For the first quarter ended March 31, 2024, total revenue was $43.8 million, of which $40.3 million was net product revenue and $3.5 million was royalty revenue. This compares to total revenue of $52.8 million in the first quarter of 2023, of which $46.8

View on SEC.gov

379 earnings releases filed in the last 30 days. Browse all earnings releases →

PUMA BIOTECHNOLOGY, INC. filing history →

Source: SEC EDGAR

accession 0001437749-24-014382

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.